메뉴 건너뛰기




Volumn 354, Issue 24, 2006, Pages 2542-2551

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

EID: 33745086350     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa055104     Document Type: Article
Times cited : (1190)

References (24)
  • 1
    • 10744233716 scopus 로고    scopus 로고
    • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
    • O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
    • (2003) N Engl J Med , vol.348 , pp. 994-1004
    • O'Brien, S.G.1    Guilhot, F.2    Larson, R.A.3
  • 2
    • 11144354274 scopus 로고    scopus 로고
    • High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia
    • Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004;103:2873-8.
    • (2004) Blood , vol.103 , pp. 2873-2878
    • Kantarjian, H.1    Talpaz, M.2    O'Brien, S.3
  • 3
    • 16844372957 scopus 로고    scopus 로고
    • Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials
    • abstract
    • Silver RT, Talpaz M, Sawyers CL, et al. Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials. Blood 2004;104:11a. abstract.
    • (2004) Blood , vol.104
    • Silver, R.T.1    Talpaz, M.2    Sawyers, C.L.3
  • 4
    • 9444289883 scopus 로고    scopus 로고
    • Combination of intensive chemotherapy with imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia
    • Towartari M, Yanada M, Usui N, et al. Combination of intensive chemotherapy with imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 2004;104:3507-12.
    • (2004) Blood , vol.104 , pp. 3507-3512
    • Towartari, M.1    Yanada, M.2    Usui, N.3
  • 5
    • 0037105560 scopus 로고    scopus 로고
    • A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias
    • Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002;100:1965-71.
    • (2002) Blood , vol.100 , pp. 1965-1971
    • Ottmann, O.G.1    Druker, B.J.2    Sawyers, C.L.3
  • 6
    • 4043137682 scopus 로고    scopus 로고
    • A randomized trial of imatinib versus chemotherapy induction followed by concurrent imatinib and chemotherapy as first-line treatment in elderly patients with de novo Philadelphia-positive acute lymphoblastic leukemia
    • abstract
    • Ottmann OG, Wassmann B, Goekbuget N, et al. A randomized trial of imatinib versus chemotherapy induction followed by concurrent imatinib and chemotherapy as first-line treatment in elderly patients with de novo Philadelphia-positive acute lymphoblastic leukemia. Blood 2003;102:226a. abstract.
    • (2003) Blood , vol.102
    • Ottmann, O.G.1    Wassmann, B.2    Goekbuget, N.3
  • 7
    • 2942567555 scopus 로고    scopus 로고
    • Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
    • Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004;103:4396-407.
    • (2004) Blood , vol.103 , pp. 4396-4407
    • Thomas, D.A.1    Faderl, S.2    Cortes, J.3
  • 8
    • 24644464172 scopus 로고    scopus 로고
    • AMN107, a novel aminopyrimidine inhibitor of p190 BCR-ABL activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells
    • Verstovsek S, Golemovic M, Kantarjian H, et al. AMN107, a novel aminopyrimidine inhibitor of p190 BCR-ABL activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer 2005;104:1230-6.
    • (2005) Cancer , vol.104 , pp. 1230-1236
    • Verstovsek, S.1    Golemovic, M.2    Kantarjian, H.3
  • 9
    • 24644435728 scopus 로고    scopus 로고
    • AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia
    • Golemovic M, Verstovsek S, Giles F, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 2005;11:4941-7.
    • (2005) Clin Cancer Res , vol.11 , pp. 4941-4947
    • Golemovic, M.1    Verstovsek, S.2    Giles, F.3
  • 10
    • 13844251975 scopus 로고    scopus 로고
    • Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
    • Erratum, Cancer Cell 2005;7:399
    • Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129-4. [Erratum, Cancer Cell 2005;7:399.]
    • (2005) Cancer Cell , vol.7 , pp. 129-134
    • Weisberg, E.1    Manley, P.W.2    Breitenstein, W.3
  • 11
    • 21144451094 scopus 로고    scopus 로고
    • In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
    • O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500-5.
    • (2005) Cancer Res , vol.65 , pp. 4500-4505
    • O'Hare, T.1    Walters, D.K.2    Stoffregen, E.P.3
  • 12
    • 33745089491 scopus 로고    scopus 로고
    • AMN107: Inhibitory profile against wild-type and mutant forms of the BCR-ABL tyrosine kinase
    • Anaheim, Calif., April 16-20, abstract
    • Manley P, von Bubnoff N, Duyster J, et al. AMN107: inhibitory profile against wild-type and mutant forms of the BCR-ABL tyrosine kinase. Presented at the 96th annual meeting of the American Association for Cancer Research, Anaheim, Calif., April 16-20, 2005. abstract.
    • (2005) 96th Annual Meeting of the American Association for Cancer Research
    • Manley, P.1    Von Bubnoff, N.2    Duyster, J.3
  • 14
    • 0023841366 scopus 로고
    • Characteristics of accelerated disease in chronic myelogenous leukemia
    • Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988;61:1441-6.
    • (1988) Cancer , vol.61 , pp. 1441-1446
    • Kantarjian, H.M.1    Dixon, D.2    Keating, M.J.3
  • 15
    • 0023634256 scopus 로고
    • Chronic myelogenous leukemia in blast crisis: Analysis of 242 patients
    • Kantarjian HM, Keating MJ, Talpaz M, et al. Chronic myelogenous leukemia in blast crisis: analysis of 242 patients. Am J Med 1987;83:445-54.
    • (1987) Am J Med , vol.83 , pp. 445-454
    • Kantarjian, H.M.1    Keating, M.J.2    Talpaz, M.3
  • 16
    • 0037186915 scopus 로고    scopus 로고
    • Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
    • Erratum, N Engl J Med 2002;346:1923
    • Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-52. [Erratum, N Engl J Med 2002;346:1923.]
    • (2002) N Engl J Med , vol.346 , pp. 645-652
    • Kantarjian, H.1    Sawyers, C.2    Hochhaus, A.3
  • 17
    • 0012906888 scopus 로고    scopus 로고
    • Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy
    • Cortes JE, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003;101:3794-800.
    • (2003) Blood , vol.101 , pp. 3794-3800
    • Cortes, J.E.1    Talpaz, M.2    Giles, F.3
  • 19
    • 0037092980 scopus 로고    scopus 로고
    • Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase
    • Kantarjian HM, Cortes J, O'Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002;99:3547-53.
    • (2002) Blood , vol.99 , pp. 3547-3553
    • Kantarjian, H.M.1    Cortes, J.2    O'Brien, S.3
  • 20
    • 20944442975 scopus 로고    scopus 로고
    • Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
    • Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005;11:3425-32.
    • (2005) Clin Cancer Res , vol.11 , pp. 3425-3432
    • Cortes, J.1    Talpaz, M.2    O'Brien, S.3
  • 21
    • 11344291101 scopus 로고    scopus 로고
    • U.S. Food and Drug Administration Drug Approval Summary: Conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval
    • Cohen MH, Johnson JR, Pazdur R. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clin Cancer Res 2005;11:12-9.
    • (2005) Clin Cancer Res , vol.11 , pp. 12-19
    • Cohen, M.H.1    Johnson, J.R.2    Pazdur, R.3
  • 22
    • 0028867826 scopus 로고
    • The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome
    • Bosma P, Chowdhury J, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995;333:1171-5.
    • (1995) N Engl J Med , vol.333 , pp. 1171-1175
    • Bosma, P.1    Chowdhury, J.2    Bakker, C.3
  • 23
    • 0038518619 scopus 로고    scopus 로고
    • Practical management of patients with chronic myeloid leukemia receiving imatinib
    • Deininger M, O'Brien S, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21:4255-6.
    • (2003) J Clin Oncol , vol.21 , pp. 4255-4256
    • Deininger, M.1    O'Brien, S.2    Ford, J.M.3    Druker, B.J.4
  • 24
    • 33745102555 scopus 로고    scopus 로고
    • Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
    • Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-41.
    • (2006) N Engl J Med , vol.354 , pp. 2531-2541
    • Talpaz, M.1    Shah, N.P.2    Kantarjian, H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.